Biogen's DZP Drug Hits Phase 3 Success for Lupus, Boosting Pipeline
BIIB sits 62% above its 52-week low of $121.05.
Summary
Biogen and UCB announced positive Phase 3 study results for dapirolizumab pegol (DZP) in systemic lupus erythematosus, showing statistically significant improvement in disease activity. This is a major positive development for Biogen's pipeline, especially following the recent failure of their Parkinson's drug, BIIB122, on May 21st. Positive Phase 3 data significantly de-risks the drug and moves it closer to regulatory submission and potential commercialization, which could add a new revenue stream for the company.
At the time of this announcement, BIIB was trading at $196.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.9B. The 52-week trading range was $121.05 to $205.97. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.